Masimo Corporation (NASDAQ:MASI) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Masimo Corporation (NASDAQ:MASI - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $191.60.

Several research firms recently weighed in on MASI. BTIG Research set a $193.00 target price on shares of Masimo and gave the company a "buy" rating in a research note on Wednesday, May 7th. Wells Fargo & Company cut their target price on shares of Masimo from $205.00 to $190.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. Raymond James Financial dropped their price objective on shares of Masimo from $204.00 to $185.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Piper Sandler reissued an "overweight" rating and issued a $200.00 price objective (down from $215.00) on shares of Masimo in a research note on Wednesday, May 7th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Masimo in a research note on Thursday, April 10th.

Masimo Stock Performance

MASI opened at $170.27 on Wednesday. The stock has a market capitalization of $9.23 billion, a price-to-earnings ratio of -18.57 and a beta of 1.19. The company has a fifty day moving average of $159.76 and a 200 day moving average of $166.76. Masimo has a fifty-two week low of $101.61 and a fifty-two week high of $194.88. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.62 and a current ratio of 2.17.

Masimo (NASDAQ:MASI - Get Free Report) last posted its earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.24 by $0.12. The company had revenue of $372.00 million during the quarter, compared to analysts' expectations of $367.79 million. Masimo had a negative net margin of 25.06% and a positive return on equity of 22.56%. Masimo's quarterly revenue was down 24.5% on a year-over-year basis. During the same period last year, the company posted $0.77 earnings per share. As a group, sell-side analysts forecast that Masimo will post 4.1 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, COO Bilal Muhsin sold 10,000 shares of the firm's stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $163.28, for a total value of $1,632,800.00. Following the completion of the sale, the chief operating officer now owns 24,172 shares in the company, valued at approximately $3,946,804.16. This trade represents a 29.26% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 16.90% of the company's stock.

Institutional Investors Weigh In On Masimo

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MASI. Jones Financial Companies Lllp bought a new stake in Masimo during the 4th quarter valued at about $27,000. Twin Tree Management LP bought a new position in shares of Masimo during the first quarter valued at approximately $29,000. Farther Finance Advisors LLC increased its holdings in Masimo by 128.9% during the first quarter. Farther Finance Advisors LLC now owns 206 shares of the medical equipment provider's stock valued at $35,000 after buying an additional 116 shares during the period. EverSource Wealth Advisors LLC raised its stake in Masimo by 40.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock worth $37,000 after buying an additional 64 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its holdings in Masimo by 31.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider's stock worth $42,000 after buying an additional 60 shares during the period. Institutional investors own 85.96% of the company's stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.